At a Glance
- Company: Biobeat Technologies, Ltd.
- Location: Petah Tikva, Israel; Boca Raton, Florida, USA
- Deal value: $50 million equity financing
- Focus area: Cuffless, patch‑worn 24‑hour ambulatory blood pressure monitoring (ABPM) for hypertension diagnosis and management
- Next steps: Hire field sales team and expand US commercialisation to make ABPM a standard of care
What happened?
Biobeat Technologies has closed a $50 million Series B equity financing round to accelerate US commercialisation of its FDA‑cleared, cuffless, patch‑worn 24‑hour ambulatory blood pressure monitoring (ABPM) system. The round was led by new investors Ally Bridge Group, OrbiMed Advisors and Elevage Medical, with participation from an unnamed strategic investor.
Why does it matter?
Hypertension affects over 100 million people in the US, but traditional cuff‑based ABPM devices suffer from low patient compliance due to disruptive inflation cycles, sleep disturbances and logistical burdens on clinical staff. Biobeat’s disposable sensor allows patients to continue normal activities undisturbed, with data automatically integrated into electronic medical records, potentially transforming ABPM into a true standard of care akin to the patch ECG revolution.
Who’s behind it?
Biobeat develops wearable, cuffless medical devices focused on remote patient monitoring, with its ABPM system designed to capture critical 24‑hour blood pressure data, including nighttime readings, for better diagnosis and treatment titration. The new board members include Steven Plachtyna (Ally Bridge), Dina Chaya (OrbiMed) and Evan Melrose (Elevage), joining Executive Chairman Raymond W. Cohen.
How was it achieved?
The financing will fund hiring a field sales team and scaling US market penetration for the clinically validated device, which eliminates the pain points of legacy ABPM by being fully disposable and generating high‑quality reports instantly upon completion of the monitoring period. CEO Arik Ben Ishay emphasised that the technology’s patient comfort and workflow efficiency position it to address widespread underutilisation of ABPM in hypertension management.
What’s next?
Biobeat plans to rapidly expand its US commercial footprint, aiming to drive ABPM adoption among clinicians treating the massive hypertensive population. The company’s leadership sees parallels to the ambulatory ECG space, where patch innovation dramatically boosted utilisation, and expects similar growth as it leverages the new capital for sales infrastructure.
What are people saying?
Executive Chairman Raymond W. Cohen hailed the investment as a validation of Biobeat’s potential to mirror the “profoundly positive impact” of patch ECG on clinical utilisation. CEO Arik Ben Ishay described this as an “exciting time” for scaling the novel ABPM system, positioning it to become a standard tool for diagnosing and titrating antihypertensive therapies.